Occult hepatitis B virus among chronic liver disease patients in Yemen

Thabit AM¹, Al–Moyed KA², Al–Balushi MS³, Hasson SS³*, Sallam TA⁴

¹Laboratory Department, Military Hospital, Sana’a, Yemen
²Department of Microbiology, Faculty of Applied Medicine and Health Sciences, Sana’a University, Sana’a, Yemen
³Department of Microbiology and Immunology, School of Medicine and Health Sciences, Qaboos University, The Sultanate of Oman
⁴Department of Community Health, Faculty of Medical Sciences, Al–Baha University, Kingdom of Saudi Arabia

ARTICLE INFO

Article history:
Received 28 October 2011
Received in revised form 3 November 2011
Accepted 13 December 2011
Available online 28 February 2012

Keywords:
Hepatitis B virus
Chronic liver disease
HBsAg
HBV–DNA

ABSTRACT

Objective: To estimate the rate of occult hepatitis B virus (HBV) among patients with chronic liver disease (CLD). Methods: After an informed consent, sera samples were collected during April 2004 to April 2005 from 280 patients (200 male and 80 female). They were previously diagnosed with CLD based on history and ultrasound and were investigated for occult HBV infection. Sera were first screened for HBsAg and those which showed negative were tested for anti–HBc. The anti–HBc positive sera were further tested for anti–HBs to identify sera with isolated anti–HBc which in turn were subjected to HBV–DNA testing using PCR to determine the rate of occult HBV infection. Moreover, sera with occult HBV were tested for Anti–HCV and HCV–RNA using RT–PCR. Results: HBsAg was detected in 44 of 280 (15.7%). Of 236 HBsAg negative sera, 22 (9.3%) were found to be anti–HBc positive sera which were further tested for anti–HBs and HBV–DNA. All anti–HBc positive sera were found to be anti–HBs negative. HBV–DNA was detected in 11 of 22 (50.0%) sera with isolated anti–HBc indicating occult HBV in 4.3% of all sera. None of the sera with occult HBV had anti–HCV or HCV–RNA. Conclusions: Occult HBV infection does exist among CLD patients in Yemen and the mechanism of its occurrence merits further investigation.

1. Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the main viruses responsible for chronic viral hepatitis with its serious sequelae. An estimate of 2 billion people have been infected with HBV with more than 350 million are chronically infected worldwide¹ and 170 million people worldwide, about 3% of the world population, are infected with HCV². The rates of chronic HBV carriers vary from 5 to 10%, among infected adolescents or adults, to up to 90% among neonates³ and the virus has been reported to be responsible for 80% of cirrhosis of the liver cases⁴.

Occult HBV is known as the presence of HBV viremia without HBsAg in presence or absence of HBV antibodies outside the window period of the acute phase⁵. Unlike conventional chronic HBV infection identified by serological markers occult HBV infection can only be identified by a molecular assay. The high sensitivity of PCR has facilitated the detection of low level of HBV genome⁶,⁷. The leading cause of occult HBV infection might be due to a mutant HBV that cannot be detected by HBsAg assays or more frequently by a virus that has suffered a strong suppression of viral replication and gene expression⁸,⁹. Occult HBV has implications on transmission through blood transfusion, reactivation among immunosuppressed individuals and interference with hepatitis C treatment⁹. It has been reported to have a role in a number of clinical phenomena including cryptogenic liver disease¹⁰, poor response to antiviral treatment¹¹ and development of hepatocellular carcinoma in chronic HCV infected patients¹². The factors that play significant roles in occurrence of occult HBV infection includes the host’s immune response, epigenetic factors and co-infection with HCV frequently reported with occult HBV¹³,¹⁴.

In this study we report the rates of occult hepatitis B among CLD patients in Yemen.

2. Materials and methods

2.1. Samples
Anonymised frozen (−20 °C) sera which were collected during the period from April 2004 to April 2005 from 280 patients who were diagnosed with CLD based on history and ultrasound was tested for HBsAg. Sera which were negative for HBsAg were tested for anti–HBc and those which showed positive anti–HBc were further tested for anti–HBs to identify sera with isolated anti–HBc. Sera with isolated anti–HBc were subjected to testing for HBV–DNA to determine the rate of occult HBV. All HBV–DNA positive sera were analysed for anti–HCV and further confirmed through HCV–RNA detection.

2.2. Serological investigations

Sera were tested for HBsAg, anti–HBc and anti–HCV using microparticle enzyme immunossay (MEIA)/ IMx system (Abbott, USA).

2.3. Nucleic acid detection

Nucleic acid extraction and amplification by two sets of primers that targets the core and surface region of HBV–DNA and 5` end non–coding region of HCV–RNA (Invitrogen, life technologies USA).

Table 1

| DNA Detected | Primer sequence | Primer description |
|--------------|-----------------|--------------------|
| HBV (5` to 3`) CCA CGT TGT AAA ACG ACG GCC AGT AAT GTC AAC AAT GTC AAC | Outer sense of core region |
| HBV (5` to 3`) CAG GAA ACA CTA ATG ACT AAC ACA GAA GCT CCA AAT TC | Outer anti-sense of core region |
| HBV (5` to 3`) ATA CCA CAG AGT CTA GAC TC | Outer sense of surface region |
| HBV (5` to 3`) AAG TGA AAC CCA AAG AGT GG | Outer anti-sense of surface region |
| HBV (5` to 3`) CAT AAG AGC ACT CTG GAC | Inner anti-sense of core region |
| HBV (5` to 3`) AAA GAA G/GTC AAG AGC GAG/CCA AAAAC/AGA | Inner–anti–sense of core region |
| HBV (5` to 3`) CCA CGT TGT AAA ACG ACG GCC AGT CTA GAC TCG TGG ACT | Inner of surface region |
| HBV (5` to 3`) CAG GAA ACA CTA ATG ACC TAC GAA CCA CTG AAC AAA TGG CAC | Inner–anti–sense of surface region |
| HCV (5` to 3`) CTGTGAGGAACTACTGTCTT | Inner sense of 5` end non–coding region |
| HCV (5` to 3`) ATACTCGAGGTCGAGCGCTTACGAGCCCTTT | Inner–anti–sense of 5` end non–coding region |
| HCV (5` to 3`) TCTGTGCTAAACTCACC | Outer sense of 5` end non–coding region |
| HCV (5` to 3`) TCACTCGAGCCAGCTAATCGGAGT | Outer anti-sense of 5` end non–coding region |

3. Results

HBsAg was detected in 44 of 280 (15.7%). Among the 236 HBsAg negative sera anti–HBc was detected in 22 of 236 (9.3%). All the anti–HBc positive sera were anti–HBs negative. HBV–DNA was detected in 11 of 22 (50.0%). Sera with isolated anti–HBc indicating occult HBV infection among 4.3% of all patients (Median age 40, ranging from 22 to 54). None of the patients with occult HBV infection had anti–HCV or HCV–RNA.

4. Discussion

A total of 4.3% of CLD patients had occult HBV infection as indicated by the detection of HBV–DNA in their sera (this is the only marker in addition to anti–HBc) using PCR assay with sensitivity of 100 copies/mL[15]. This has not been previously reported from Yemen. The absence of HBsAg in these patients is unlikely to be ascribed to false negative test results but due to very low HBsAg concentrations, as the assay used has a “reported” sensitivity of 97.7%. Concomitant HCV infection has been well documented to down regulate HBV replication and to suppress expression of HBsAg[16–18]. None of the patients had an HCV co–infection by a serological assay and RT–PCR. However, it is unknown whether these patients had previously recovered from HCV infection (as a result of influence of HBV co-infection). Early study by Chu et al reported that the persistence of HCV and antibody response to it was found to be inhibited by active replication of HBV[19]. In addition to that occult HBV infection has been reported to associate with HIV[20–22]. However, absence of data on the status of HCV–RNA and HIV antibodies limited drowning a conclusion on the role of the HCV and HIV co–infection in development of occult hepatitis among our patients. The origin of occult HBV has been hypothesized to be due to mutations in the regulatory regions of the HBV genome[23]. A novel splicing event of HBV–RNA has been suggested to abolishes surface protein
expression without affecting other functions encoded in the virus genome P, C and X. Whether or not this had happened in our patients is not clear. However these patients might be at risk of reinfection and might become candidates for orthotopic liver transplants. Moreover, immunosuppressive treatment may also put this patient at risk of reactivation. As occult hepatitis B is increasingly reported among patients with CLD[24–29] awareness of this condition among clinician should be increased with an ultimate aim of proper management of such patients. Consequently, how relevant the CLD among our patient is to their occult HBV infection merits further investigation.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

The authors would like to extend deep thanks to the Laboratory Department, Military Hospital, Sana’a, Yemen and Sana’a University, Republic of Yemen, Department of Microbiology, Faculty of Medicine and Health Sciences, Sana’a, Yemen.

References

[1] Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Viral Hepat 2004; 11(2): 97–107.
[2] Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli–Vergani G, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26: Suppl 48: S39–47.
[3] Glebe D. Recent advances in hepatitis B virus research: a German point of view. World J Gastroenterol 2007; 13(1): 8–13.
[4] Tandon BN, Acharya SK, Tandon A. Epidemiology of hepatitis B virus infection in India. Gut 1996; 38: Suppl 2: S56–59.
[5] Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011; 17(36): 927–938.
[6] Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol 2011; 17(12): 1553–1557.
[7] Wolff FH, Fuchs SC, Brandão AB. Absence of occult hepatitis B among blood donors in southern Brazil. Braz J Infect Dis 2011; 15(2): 159–162.
[8] Raimondi G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46(1): 160–170.
[9] Schmelitzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 2010; 55(12): 3328–3335.
[10] Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of non–response to antiviral therapy of chronic hepatitis C. J Med Virol 2007; 79: 1075–1081.
[11] Larnubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol 2011; 17(12): 1529–1530.
[12] Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T, et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res 2008; 38: 546–556.
[13] Veropalumbo E, Marrone A, Vallefuoco L, Perruolo G, Orlando R, Scordino F, et al. Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays. Interreviro 2010; 53: 183–187.
[14] Selim HS, Abou–Donia HA, Taha HA, El Azab GL, Bakry AF. Role of occult hepatitis B virus in chronic hepatitis C patients with flare of liver enzymes. Eur J Intern Med 2011; 22: 187–190.
[15] Sallam TA, Tong CYW. Two distinct types of hepatitis B virus core promoter variants in Yemeni blood donors. J Med Virol 2002; 68: 328–334.
[16] Halima SB, Bahri O, Maamouri N, Cheikh I, Alaya NB, Sadraoui A, et al. Serological and molecular expression of Hepatitis B infection in patients with chronic hepatitis C from Tunisia, North Africa. Virol J 2010; 15: 229.
[17] Chakravarti A, Verma V, Jain M, Kar P. Characteristics of dual infection of hepatitis B and C viruses among patients with chronic liver disease: a study from tertiary care hospital. Trop Gastroenterol 2005; 26: 183–187.
[18] Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during hepatitis B virus infection. J Infect Dis 1992; 165: 831–834.
[19] Chu CM, Yeh CT, Sheen IS, Liaw YF. Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV. Gut 2002; 51: 95–99.
[20] Liang HX, Chen YY, Zhou R, Zhang Q, Pan YF, Gu JS, et al. A cross–sectional survey of occult hepatitis B virus infection in HCV–infected patients in acquired immune deficiency syndrome area. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010; 24(6): 442–444.
[21] Marque–Juillet S, Bengalhia K, Monnier S, Fernand–Laurent M, Mazeron MC, Harzie M. Should patients infected with HIV be screened for occult hepatitis B? Pathol Biol (Paris) 2010; 58(2): e39–42.
[22] Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81(5): 441–445.
[23] Schmelitzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 2010; 55(12): 3328–3335.
[24] Barth RE, Huijgen Q, Tempelman HA, Mudrikova T, Wensing M, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C from Tunisia, North Africa. Viral J 2010; 15: 229.
[25] Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Houspie L, Verbeeck J, Rahman M, et al. Molecular characterization of hepatitis B virus strains circulating in Belgian patients coinfected with HIV and HBV: overt and occult infection. J Med Virol 2011; 83: 929–934.
[26] Al–Shamiri AH, Al–Taj MA, Ahmed AS. Prevalence and coinfections of schistosomiasis/hepatitis B and C viruses among school children in an endemic areas in Taiz, Yemen. Asian Pac J Trop Med 2011; 4(5): 404–408.
[27] Aemrn PT, Sar TT, Torchlka SH. Prevalence of plasmocytoma and hepatitis B virus co–infection in blood donors at Bishop Murray Medical Centre, Makurdi, Benue State, Nigeria. Asian Pac J Trop Med 2011; 4(3): 224–226.
[28] Abdel–Hady El–Gilany, Sabry Hammad, Khaled Refaat, Reda Al–Enazi. Seroprevalence of hepatitis A antibodies among children in a Saudi community. Asian Pac J Trop Med 2010; 3(4): 278–282.
[29] Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus–positive patients. Liver Int 2003; 23(1): 12–18.